



Cite this: *Org. Biomol. Chem.*, 2016, **14**, 1599

Received 1st December 2015,
Accepted 24th December 2015

DOI: 10.1039/c5ob02461g

www.rsc.org/obc

Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD)[†]

Nick Palmer, Torren M. Peakman, David Norton and David C. Rees*

This study describes general synthesis aspects of fragments for FBDD, as illustrated by the dihydroisoquinolones **1–3**. Previous Rh(III) methodology is extended to incorporate amines, heteroatoms (N and S), and substituents (halogen, ester) as potential binding groups and/or synthetic growth points for fragment-to-lead elaboration.

Introduction

Fragment-based drug discovery

FBDD is well-established within many Pharma, biotech and academic institutions as a technology for generating new chemical matter for drug discovery.¹ Over 20 compounds derived from fragment-based drug discovery (FBDD) are being evaluated in clinical trials² and the BRAF kinase inhibitor, vemurafenib (Zelboraf) is a launched drug for late stage melanoma.³

Organic chemistry is one of the enabling sciences required for FBDD and has been critical for the successful development of this field during the last decade. However, as FBDD has developed it has unearthed a pressing need to design and synthesise more fragments and to develop new synthetic methodology to convert fragments into leads. The successful prosecution of FBDD projects often requires new organic synthesis methodology which, not surprisingly, is frequently time-critical. This is increasingly an issue as more difficult protein drug discovery targets are screened. There are two areas in particular that need synthetic methodology research: (1) the design and synthesis of new fragments and (2) the elaboration of low affinity (μM or mM) fragments into high affinity (nM) leads using precisely controlled synthetic growth points (vectors).

Compared to drugs or high throughput screening (HTS) compounds, fragments are small, simple molecules. A key advantage of screening low MW fragments (in comparison with higher MW, HTS-like compounds) is the improved hit rate resulting from screening such small compounds. Fragments are designed to form efficient binding interactions with protein targets but, due to their small size, the typical binding

affinity of a fragment is only mM or μM . Table 1⁴ summarises guidelines indicating some of the chemical properties that we use today as part of the selection process for adding new fragments into the Astex screening library. These guidelines have evolved significantly compared to earlier descriptions of fragments as a result of 10 years of screening fragments by X-ray crystallography and other biophysical techniques.⁵ There are many other publications describing fragment library design⁶ and there are fragments with properties outside those listed in Table 1 that have been used to generate useful leads, so this is still an emerging area.

To grow fragments into leads requires the incorporation of additional binding groups to interact with the protein target.

Table 1 Aspirational properties of many Astex fragments

Property	Guideline
Molecular recognition	Diverse, usually polar groups for binding to a protein (a single pharmacophore). An aspiration is to express any given binding pharmacophore in a variety of chemotypes
Synthetic vectors	Multiple synthetically accessible positions for fragment growth in 3 dimensions to form new binding interactions
Physico-chemical properties	Molecular weight: ~ 140 – 230 Non-hydrogen atoms: 10 – 16 Lipophilicity ($\text{clog } P$): ~ 0.0 to 2.0 Properties commensurate with biophysical screening at high concentrations, e.g., aqueous solubility (preferably $\geq 5 \text{ mM}$ in $5\% \text{ DMSO}$, or other screening co-solvents); stability ($> 24 \text{ h}$ in solution); avoid compounds/functional groups known to be associated with high reactivity, aggregation in solution, or false positives. NB: aromatic C–H bonds may assist NMR screening
Synthetic tractability	Typically, ~ 50 – 100 mg and ≤ 4 steps from commercially available reagents
Shape	Variety of 2- and 3-dimensional shapes for each scaffold and pharmacophore Number of freely rotatable bonds: 0 – 3 Number of chiral centres: 0 – 1 , sometimes 2

Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, UK. E-mail: david.rees@astx.com

[†]Electronic supplementary information (ESI) available. See DOI: 10.1039/c5ob02461g






Fig. 1 Dihydroisoquinolones with attractive fragment-like properties.†

For this, it is desirable to rapidly elaborate the fragment in any direction with either polar or non-polar groups, ideally with regio- and stereo-control utilising synthetic methodology that has been worked out in advance. These requirements place big demands on synthetic methodology and represent an opportunity to significantly improve FBDD.

Selection of dihydroisoquinolones as fragments

Dihydroisoquinolone (1, Fig. 1) is a simple, small molecule (MW = 147, clog *P* = 1.0) and contains a strong hydrogen-bonding motif in the form of the *cis*-amide. Low complexity⁸ plus a polar binding motif are important factors to increase the probability of a fragment being a screening hit. The related fragments 2 and 3 are examples of compounds that could be made after 1 is identified as a fragment hit from a screening campaign. Furthermore, compounds 2 and 3 are attractive as fragments in their own right due to:

- low MW (177, 204 respectively) and low clog *P* (0.32, 1.3 respectively)
- sufficient aqueous solubility (>5 mM) for screening
- polar H-bonding groups (amide + alcohol/amine)
- numerous positions available for synthetic elaboration (fragment-to-lead stage)

Thus, we selected the dihydroisoquinolones 2 and 3 as prototype examples to develop an FBDD-friendly synthetic methodology. The synthesis of fragment 2 has been reported previously using Rh(III) catalysed C–H bond activation methodology (Fig. 2).⁹ This synthesis uses readily available starting materials; proceeds at room temperature with no requirement to exclude air; is amenable to >100 mg scale and frequently the two regioisomers (a and b) can be separated by chromatography. Whilst both of these regioisomers meet many of the guidelines in Table 1 we prefer fragments not to have distally separated polar binding groups hence we prefer isomer (a) for FBDD. The methodology in Fig. 2 utilises catalytic rhodium C–H bond activation and has been developed in




Fig. 2 Previously published synthesis of dihydroisoquinolones utilising Rh(III) catalytic C–H activation.^{9,10c}




Fig. 3 Schematic representation of synthetic elaboration of fragment 1. Growth positions are shown as blue arrows and the incorporation of aromatic heteroatoms and polar binding groups are indicated.

several subsequent publications.¹⁰ The mechanism is thought to involve metal coordination to the nitrogen moiety which directs cyclometalation to the *ortho* C–H bond. Alkene insertion occurs *via* coordination to the metal and the acyl protecting group acts as an internal oxidant. This methodology has also been reported with alkynes leading to isoquinolones and extended to substituted alkenes (for dihydroisoquinolones).^{9–11} The versatility of the methodology is further illustrated with other publications that describe, for related systems, chiral induction at the asymmetric carbon utilising an engineered metalloenzyme^{10d,e,12} or controlling the ratio of the two regioisomers by modulating the steric properties of the Rh(III) catalyst.^{10b}

Extending the dihydroisoquinolone methodology for FBDD


Despite the modern synthetic methodology of Fig. 2 and the attractive fragment properties, we perceived some additional requirements from an FBDD perspective. Firstly, many drugs contain amino groups or heterocyclic aromatic rings. Fortunately, some methodology for incorporating heteroatoms into compounds related to 2 is known^{10a,b} and we sought to apply this methodology to the functionalised dihydroisoquinolone fragments. Secondly, our FBDD projects are frequently challenged by having to work out methodology to access synthetic growth points or vectors in 3D space. One fragment may bind to different protein targets, requiring different synthetic vectors in each case, as deduced by examining the protein-fragment X-ray crystal structure. An attraction of the dihydroisoquinolone fragment template is the numerous positions available for synthetic elaboration during the fragment-to-lead stage; these are shown in Fig. 3 as blue arrows. The Rh(III) methodo-

† clog *P* is calculated from Daylight version 4.93 <http://www.daylight.com/products/toolkit.html>.

Solubility measurements were carried out by ¹H quantitative NMR at 500 MHz using the QNANTAS approach.¹⁹ Aliquots of fragments (100 mM in DMSO-d₆) were diluted $\times 20$ with buffer (40 mM phosphate, 100 mM TRIS, 15% D₂O, pH = 7.1) to afford samples with nominal concentrations of 5 mM. A 2.5 mM sample of *p*-hydroxybenzoic acid, prepared by dilution of a 50 mM stock in DMSO-d₆ $\times 20$ with buffer was used as the qNMR standard.



Table 2 Reaction with functionalised alkenes

				
Alkene	Product a	Product b	Isolated yield %	Regio-selectivity (ratio a : b estimated by NMR)
			59	>20 : 1
			a + b: 93	1 : 1
			6a:42 6b:42	1 : 1
			63	>20 : 1
			74	>20 : 1

logy has already been shown to permit several of these growth points into fragment 1.^{9,10,10c-e}

Results and discussion

Use of substituted alkenes to give polar functionality for protein binding and/or further synthetic elaboration (Table 2)

Compound 4 is readily available following literature procedures^{10c} and was used to explore reactions with mono substituted alkenes. The alkenes selected were chosen to expand those previously described in the literature and allow introduction of new (protected) functional groups useful for subsequent transformations or protein binding interactions.

Reaction with *N,N*-dimethyl allylamine gives a single regioisomeric product, 3 (59% after 24 h, note long time required possibly due to the basic amine coordinating to the catalyst). This is the first example that we are aware of where an amino substituted alkene is used in this procedure. Compound 3 is interesting as a fragment itself, HAC = 15, MW = 204, clogP = 1.3, measured solubility ≥ 5 mM, (Fig. 1). This led us to explore this alkene in more functionalised systems (see Tables 3 and 4).

The silyl protected allyl alcohol and Boc protected allyl amine gave the cyclised products 5a,b and 6a,b respectively as

Table 3 Ar-substituted hydroxamates plus *N,N*-dimethyl allylamine













		
9 R=4-Br		
10 R=3-Br		
11 R=4-CO2Me		
12 R=3-CO2Me		
Hydroxamate	Product	Isolated yield %
		54
		53
		84
		56



Table 4 Thiophene analogues

 <p>17 R=H 18 R=Br</p> <p>a b</p>				
Hydroxamate	Product a	Product b	Isolated yield %	Regio selectivity (ratio a : b)
R = H	 19a		31	8 : 1 ^a
R = H	 20a	 20b	a:24 b:55	1 : 2
R = H	 21a	 21b	a:27 b:52	1 : 2
R = Br	 22a		30	>20 : 1
R = Br	 23a	 23b	a + b:52	1 : 1
R = Br	 24a	 24b	a:25 b:29	1 : 1

^a Isomer ratio determined by LCMS, minor isomer not isolated.

1 : 1 mixtures of regioisomers in good yields. These protected hydroxyl and amino substituted analogues can be deprotected to provide groups capable of forming new polar binding interactions and/or synthetic growth vectors. Benzyl substituted acrylamide gives a single regioisomer, **7a** (63%). This is the first example that we are aware of using an amide in this transformation (but note that **7a** has been synthesised previously by a different route¹³ and is commercially available in milligram quantities). If this growth vector is required, the formation of a single regioisomer is an advantage. Acrolein diethylacetal gives a single regioisomer, **8a** (74%) and again the protected aldehyde can provide a handle for a range of subsequent transformations.

We selected aromatic bromides and esters for incorporation into the hydroxamates to probe the methodology for fragment-to-lead elaboration (Table 3). Note that compounds **13–16** are

not designed to be fragments themselves. Rather, their synthesis builds confidence that if fragment **3** binds to a protein with an interaction that shows opportunity for elaboration *via* the *meta* or *para* positions, synthetic methodology is already established to follow-up rapidly.

Modest to good yields and a single regioisomer are observed for **13**, **14**, **16**. The *meta*-bromo substituted analogue **10** gave a small amount of product corresponding to cyclisation onto the position *ortho* to the bromine. This product was not isolated in a pure form, but ¹H NMR of a mixed fraction was consistent with this isomer (see ESI†).

There is some precedent for using the *para*-methyl ester substituted hydroxamate, **11**^{10c,14} but the *meta*-methyl ester substituted hydroxamate, **12** has not been reported previously.

In our hands preliminary attempts to cyclise with *ortho* Br or OMe substituted hydroxamates were unsuccessful perhaps



due to unfavourable steric interactions between the *ortho* substituent and the hydroxamate carbonyl (data not shown). An *ortho* iodide substituent on a closely related system has been reported¹⁵ but this remains an area requiring additional research.

Application of methodology to heteroaromatic analogues (Table 4 and Scheme 1)

Incorporating heteroatoms into aromatic rings of fragments is highly desirable in order to: modulate physicochemical properties (clogP, solubility *etc.*); probe fragment binding interactions; increase opportunities for fragment-to-lead synthetic elaboration, and to subtly alter the growth vectors. Hence, we investigated three heterocycles commonly found in biologically active leads and drugs: thiophenes, thiazoles and pyridines.

There are a few reports of the Rh(III) methodology being applied to thiophenes¹¹ and pyridines¹⁶ (compound 17 has been used with a vinyl ester¹¹) but from a fragment perspective the scope of the methodology is limited and we are not aware of thiazoles being used previously.

The thiophenes in Table 4 are derivatised with the same (protected) polar groups used above: amines, alcohols and amides. The aromatic bromo substituents provide potential synthetic growth points for the fragment-to-lead stage.

N,N-Dimethyl allyl amine reacted with both the substituted and unsubstituted thiophenes to give **19a** and **22a** (31, 30% yields unoptimised). Compound **19a** can be considered as a fragment itself (HAC = 14, MW = 210, clogP = 1.1) and since aromatic sulphurs are known to form binding interactions with carbonyls they provide an additional protein binding possibility. Reaction of the thiophene hydroxamates **17** and **18** with the TBDMS protected allyl alcohol gives **20a,b** and **23a,b** respectively and Boc protected allyl amine gives **21a,b** and **24a,b** in good yields and with a similar isomer ratio.

Scheme 1 extends the method to thiazoles. The chloro thiazole hydroxamate, **25** was prepared using the standard conditions and treatment with TBDMS protected allyl alcohol

generated the two expected isomers **26a** and **26b** in a 1:4 ratio. Removal of the silyl group produced a mixture of regioisomers that could be separated into **27a** and **27b**, albeit in low yield (4% and 42% respectively) (Scheme 1). Unoptimised attempts to use *N,N*-dimethyl allyl amine failed in this reaction. The TBDMS-protected alkene also reacted with the unsubstituted thiazole **28**, although the unoptimised yield of **29a,b** was low (16%) and regioisomer **b** is the major product.

Based upon literature precedent this methodology was known to be less suitable for pyridyl analogues due to the lower reactivity of these electron deficient systems and formation of regioisomer mixtures. This has been overcome to some extent by the use of a pyridine *N*-oxide to increase the reactivity of the pyridine ring.^{10a} Compound **30** (Scheme 1), synthesised following standard procedures, was treated with *N,N*-dimethyl allylamine to give a mixture of isomers and **31** was isolated by preparative HPLC but the (unoptimised) yield is only 8% and as previously noted, higher catalyst loading was used. Our results indicate that this methodology is not yet ideal for heterocycles and given their importance in drug discovery this is another area that would benefit from additional research.

Conclusions


The emergence of FBDD has created new demands for organic synthesis. Despite the apparent simplicity of fragment-like compounds they present significant and growing challenges, *e.g.*, methodology to design and synthesise new fragments and methodology to grow fragments into high affinity chemical leads *via* synthetic growth points (vectors) according to the particular fragment-protein binding interactions. These two aspects are frequently rate limiting in FBDD.

This study identified the dihydroisoquinolones, **1–3** as having attractive fragment-like chemical properties (see Table 1). A published method to synthesise compound **2** utilising Rh(III) catalysed C–H bond activation^{9,10c} has been extended to increase the utility of this template for fragment-based drug discovery. We have focused on:

- Adding polar side chains capable of exploring new binding interactions with proteins (tertiary amines and protected amines, alcohols and amides).
- Incorporating S and N heteroatoms into the aromatic ring to modulate logP, solubility, synthetic growth vectors *etc.*
- Adding functional groups that can be used as synthetic points for fragment growth during fragment-to-lead optimisation (aromatic bromides and esters).

These results illustrate frequently encountered synthetic organic chemistry challenges that we face in FBDD including:

- Synthetic methodology that is not exemplified in the presence of heterocyclic aromatics and polar functional groups *e.g.* amines.
- Synthetic methodology that is not exemplified for water soluble compounds (we require low lipophilicity, Table 1).



Scheme 1



- Requirement for multiple, synthetically accessible fragment growth positions (Fig. 3) and methodology that allows regio- and stereo-selective fragment growth in the presence of polar functionality.

Some of the chemistry methodology challenges for FBDD are similar to other drug discovery techniques including HTS, *e.g.* the desire to incorporate polar side chains and heteroatoms into lead molecules.¹⁷ Others, such as the small size and lipophilicity of fragments; the requirement for synthetic vectors in multiple directions; and the drive to use X-ray crystallography to design bespoke synthetic targets, are more evident in FBDD laboratories. We see a pressing need for even more synthetic organic chemists to engage with these challenges.

Experimental

General experimental

All reactions were carried out without exclusion of air or moisture unless otherwise stated. Commercial solvents and reagents were used without further purification. Reactions were monitored by HPLC-MS on an Agilent 1200 series instrument, coupled with an Agilent 1200 MWD SL UV detector and Agilent 6140 single quadrupole mass detector. Normal phase flash chromatography was performed using a Biotage Isolera and silica SNAP cartridges. Petrol refers to petroleum ether (b.p. 40–60 °C). Reverse phase chromatography was performed using a Biotage SP4 and Biotage C18 Ultra cartridges with an acetonitrile in water gradient, without use of modifiers. Preparative HPLC was performed on an Agilent 1260 instrument, using Waters prep columns (Atlantis prep T3 OBD 5 μ m 100 \times 19 mm, Sunfire prep C18 OBD 5 μ m 100 \times 19 mm or XBridge C18 5 μ m OBD 100 \times 19 mm). HRMS (ESI) spectra were recorded on an Agilent 6550 QTOF instrument.

¹H, ¹³C, ¹³C-Dept, COSY, HSQC and HMBC NMR spectra were recorded using Bruker 400 MHz or 500 MHz spectrometers (CDCl₃ or d₆-DMSO as solvent). Chemical shifts for ¹H and ¹³C NMR spectra are reported as δ in units of parts per million (ppm) downfield from SiMe₄ (δ 0.0) using the chemical shifts of the residual solvent peaks. Multiplicities are given as: s (singlet); brs (broad singlet); d (doublet); t (triplet); q (quartet); dd (doublets of doublet); td (triplet of doublet); m (multiplets) *etc.* Coupling constants are reported as *J* values in Hz. ¹³C chemical shifts were measured using direct ¹³C NMR or *via* 2D HSQC and HMBC spectra.

Preparation of *N*-pivaloyloxy amide starting materials

General procedure A. Step 1: to a suspension of the carboxylic acid (20 mmol, 1.0 eq.) in dry CH₂Cl₂ (20 mL) at room temperature under a nitrogen atmosphere was added a catalytic amount of dry DMF (4 drops). Oxalyl chloride (15 mL, 30 mmol, 1.5 eq., 2 M soln in DCM) was added dropwise over about 20 minutes with care as effervescence occurs. The reaction was allowed to stir at room temperature until completion which was judged to be when no further effervescence could be seen and in some cases, the solution became

homogeneous. The solvent was then removed under reduced pressure to afford the corresponding crude acid chloride.

Step 2: hydroxylamine hydrochloride (1.39 g, 20 mmol, 1 eq.) was added to a biphasic mixture of K₂CO₃ (5.52 g, 20 mmol, 2.0 eq.) in a 2 : 1 mixture of EtOAc (40 mL) and H₂O (20 mL). The resulting solution was cooled to 0 °C followed by dropwise addition of the crude acid chloride dissolved in a minimum amount of EtOAc. The flask containing the acid chloride was then rinsed with additional EtOAc. The reaction was allowed to warm to room temperature which in most cases resulted in formation of a thick white suspension of the hydroxamic acid. The reaction was stirred for 4 h to allow complete conversion of the acid chloride to hydroxamic acid then pivaloyl chloride (2.46 mL, 20 mmol) was added dropwise. The reaction can be monitored by TLC and HPLC and also the thick white precipitate dissolves as the reaction proceeds and the hydroxamic acid is consumed. Further pivaloyl chloride can be added if required. The phases were separated and the aqueous phase was extracted twice with EtOAc. The combined organic layers were dried over MgSO₄, filtered, and evaporated under reduced pressure. The crude products were purified by flash column chromatography using an appropriate solvent mixture of petrol/EtOAc as eluent.

Phenylformamido 2,2-dimethylpropanoate (4).¹⁸ Triethylamine (2.03 mL, 14.59 mmol, 1 equiv.) was added to a suspension of *N*-hydroxybenzamide (2.0 g, 14.59 mmol, 1 equiv.) in dichloromethane (30 mL). The reaction mixture was cooled to 0 °C in an ice bath then pivaloyl chloride (1.79 mL, 14.59 mmol, 1 equiv.) was added dropwise. The resulting mixture was allowed to warm to room temperature and stirred for 2 hours. The reaction was diluted with DCM, transferred to a separating funnel and washed with water then brine. The organic layer was dried over MgSO₄, filtered and evaporated under reduced pressure. The crude material was purified by flash chromatography using a gradient of 0–30% ethyl acetate in petrol as eluent. The product was obtained as a white solid (2.4 g, 74% yield). δ_{H} (400 MHz, chloroform-*d*) 9.43 (1 H, s), 7.89–7.72 (2 H, m), 7.62–7.50 (1 H, m), 7.50–7.38 (2 H, m), 1.35 (9 H, s). δ_{C} (101 MHz, chloroform-*d*) 177.17, 166.92, 132.81, 131.08, 128.93, 127.61, 38.61, 27.17.

(4-Bromophenyl)formamido 2,2-dimethylpropanoate (9).¹¹ Synthesised according to general procedure A, step 2 on a 20 mmol scale, starting with commercially available acid chloride. The crude material was purified by flash chromatography using a gradient of 0–20% ethyl acetate in petrol as eluent. The product was obtained as a white solid (4.8 g, 80% yield). δ_{H} (400 MHz, DMSO-*d*₆) 12.37 (1 H, s), 7.75 (4 H, s), 1.28 (9 H, s).

(3-Bromophenyl)formamido 2,2-dimethylpropanoate (10).^{11,16} Synthesised according to general procedure A, step 2 on a 20 mmol scale, starting with commercially available acid chloride. The crude material was purified by flash chromatography using a gradient of 0–30% ethyl acetate in petrol as eluent then recrystallised from Et₂O/petrol. The product was obtained as a white solid (2.4 g, 40% yield). δ_{H} (400 MHz, DMSO-*d*₆)



12.41 (1 H, brs), 7.97 (1 H, t, J 1.9), 7.82 (2 H, dd, J 7.9, 1.9), 7.50 (1 H, t, J 7.9), 1.29 (9 H, s).

Methyl 4-[[[(2,2-dimethylpropanoyl)oxy]carbamoyl]benzoate (11). Synthesised according to general procedure A on a 20 mmol scale, starting with commercially available carboxylic acid. The crude material was purified by flash chromatography using a gradient of 0–30% ethyl acetate in petrol as eluent. The product was obtained as a white solid (2.837 g, 50% yield over 3 steps). δ_{H} (400 MHz, DMSO- d_6) 12.47 (1 H, brs), 8.18–8.02 (2 H, m), 8.02–7.87 (2 H, m), 3.89 (3 H, s), 1.29 (9 H, s). δ_{C} (101 MHz, DMSO- d_6) 175.51, 165.49, 163.60, 135.15, 132.61, 129.36, 127.71, 52.39, 37.78, 26.76. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{14}H_{17}NO_5$ 280.1185; found: 279.1122 δ = 3.57 ppm.

Methyl 3-[[[(2,2-dimethylpropanoyl)oxy]carbamoyl]benzoate (12).¹¹ Synthesised according to general procedure A on a 20 mmol scale, starting with commercially available carboxylic acid. The crude material was purified by flash chromatography using a gradient of 0–30% ethyl acetate in petrol as eluent. The product was obtained as a white solid (1.477 g, 26% yield over 3 steps). ^1H NMR (400 MHz, DMSO- d_6) δ 12.49 (1 H, brs), 8.42 (1 H, t, J 1.6), 8.16 (1 H, dt, J 7.9, 1.6), 8.08 (1 H, dt, J 7.9, 1.6), 7.69 (1 H, t, J 7.9), 3.90 (3 H, s), 1.29 (9 H, s). ^{13}C NMR (101 MHz, DMSO- d_6) δ 175.57, 165.48, 163.53, 132.54, 131.90, 131.64, 130.04, 129.33, 127.92, 52.37, 37.78, 26.76. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{14}H_{17}NO_5$ 280.1185; found: 280.1197. δ = 4.28 ppm.

(Thiophen-2-yl)formamido 2,2-dimethylpropanoate (17). Triethyl amine (0.972 ml, 6.99 mmol, 1 equiv.) was added to a suspension of *N*-hydroxythiophene-2-carboxamide (1.0 g, 6.99 mmol, 1 equiv.) in THF (10 mL). The reaction mixture was cooled to 0 °C in an ice bath then pivaloyl chloride (0.86 mL, 6.99 mmol, 1 equiv.) was added dropwise. The resulting mixture was allowed to warm to room temperature and stirred for 2 hours. The reaction was diluted with EtOAc, transferred to a separating funnel and washed with water then brine. The organic layer was dried over MgSO_4 , filtered and evaporated under reduced pressure. The crude material was purified by flash chromatography using a gradient of 0–30% ethyl acetate in petrol as eluent. The product was obtained as an off-white solid (1.22 g, 77% yield). δ_{H} (400 MHz, DMSO- d_6) 12.25 (1 H, brs), 7.88 (1 H, dd, J 5.0, 1.2), 7.74 (1 H, dd, J 3.7, 1.2), 7.20 (1 H, dd, J 5.0, 3.7), 1.28 (9 H, s). δ_{C} (101 MHz, DMSO- d_6) 175.67, 159.83, 134.95, 131.96, 129.38, 128.12, 37.75, 26.75. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{10}H_{13}NO_3S$ 228.0689; found: 228.0692. δ = 1.32 ppm.

(4-Bromothiophen-2-yl)formamido 2,2-dimethylpropanoate (18). Synthesised according to general procedure A, step 2 on a 9.66 mmol scale, starting with commercially available acid chloride. The crude material was purified by flash chromatography using a gradient of 0–30% ethyl acetate in petrol as eluent. The product was obtained as an off-white solid (1.5 g, 50% yield). δ_{H} (400 MHz, DMSO- d_6) 12.43 (1 H, brs), 8.03 (1 H, d, J 1.5), 7.72 (1 H, d, J 1.5), 1.28 (9 H, s). δ_{C} (101 MHz, DMSO) 176.03, 158.91, 136.76, 131.55, 130.27, 109.61, 38.29, 27.22.

HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{10}H_{12}BrNO_3S$ 305.9794; found: 305.9802. δ = 2.61 ppm.

(2-Chloro-1,3-thiazol-5-yl)formamido 2,2-dimethylpropanoate (25). Synthesised according to general procedure A on a 12 mmol scale, starting with commercially available carboxylic acid. The crude material was purified by flash chromatography using a gradient of 0–50% ethyl acetate in petrol as eluent. The product obtained is an off white solid (1.818 g, 57% yield over 3 steps). δ_{H} (400 MHz, DMSO- d_6) 12.69 (1 H, brs), 8.21 (1 H, s), 1.27 (9 H, s). δ_{C} (101 MHz, DMSO- d_6) 175.36, 157.11, 154.70, 142.98, 133.24, 37.80, 26.67. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_9H_{11}ClN_2O_3S$ 263.0252; found: 263.0261. δ = 3.42 ppm.

(1,3-Thiazol-5-yl)formamido 2,2-dimethylpropanoate (28). Synthesised according to general procedure A, step 2 on a 15.5 mmol scale, starting with commercially available acid chloride. The crude material was purified by flash chromatography using a gradient of 0–100% ethyl acetate in petrol as eluent. The product obtained is a yellow oil (0.502 g, 14% yield). δ_{H} (400 MHz, DMSO- d_6) 9.75 (1 H, brs), 9.20 (1 H, d, J 0.7), 8.32 (1 H, d, J 0.7), 1.25 (9 H, s). δ_{C} (101 MHz, DMSO- d_6) 175.51, 158.92, 157.47, 143.90, 132.64, 37.82, 26.90. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_9H_{12}N_2O_3S$ 229.0641; found: 228.0578. δ = 4.37 ppm.

(2-Bromopyridin-4-yl)formamido 2,2-dimethylpropanoate (30). Synthesised according to general procedure A on a 20 mmol scale, starting with commercially available carboxylic acid. The crude material was purified by flash chromatography using a gradient of 0–20% ethyl acetate in petrol as eluent. The product was obtained as an off-white solid (2.21 g, 36% yield over 3 steps). δ_{H} (400 MHz, DMSO- d_6) 12.75 (1 H, brs), 8.60 (1 H, dd, J 5.1, 0.8), 7.94 (1 H, brs), 7.76 (1 H, dd, J 5.1, 1.5), 1.29 (9 H, s). δ_{C} (101 MHz, DMSO- d_6) 175.24, 161.05, 151.53, 141.87, 141.20, 125.48, 120.96, 37.81, 26.69. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{11}H_{13}BrN_2O_3$ 301.0182; found: 301.0194. δ = 3.99 ppm.

Synthesis of 3,4 dihydroisoquinolones

General procedure B. Without any particular precautions to exclude oxygen or moisture, the pivaloyl-protected hydroxamic acid (1 equiv.), $[\text{Cp}^*\text{RhCl}_2]_2$ (1 mol%) and CsOAc (2 equiv.) were weighed into a 5 mL CEM microwave tube equipped with a stirrer bar. MeOH (0.2 M) was then added followed immediately by the alkene (1.1 equiv.). The reaction was stirred at room temperature for 16 hours or if necessary, heated up to 65 °C in the CEM microwave for between 2–7 hours. The reaction was diluted with EtOAc washed with Na_2CO_3 sat. aq. then brine. The combined organic layers were dried over MgSO_4 , filtered and evaporated under reduced pressure. The crude products were purified by flash column chromatography on a Biotage using an appropriate solvent mixture of petrol/EtOAc or EtOAc/MeOH as eluent.

3-[(Dimethylamino)methyl]-1,2,3,4-tetrahydroisoquinolin-1-one (3). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a



gradient of 0–10% MeOH in EtOAc. The desired compound was obtained as a brown solid in 59% yield (55 mg) from phenylformamido 2,2-dimethylpropanoate (**4**) (0.45 mmol, 100 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.88–7.81 (1 H, m), 7.48 (1 H, td, J 7.5, 1.5), 7.41 (1 H, brs), 7.37–7.32 (1 H, m), 7.32–7.28 (1 H, m), 3.72 (1 H, dtdd, J 9.0, 7.1, 4.8, 2.1), 3.01 (1 H, dd, J 15.8, 4.8), 2.79 (1 H, dd, J 15.8, 9.0), 2.35 (1 H, dd, J 12.0, 7.1), 2.27 (1 H, dd, J 12.0, 7.1), 2.18 (s, 6H). δ_{C} (101 MHz, DMSO- d_6) 164.60, 138.50, 132.37, 129.04, 128.24, 127.38, 127.13, 63.28, 48.24, 45.98, 31.90. HRMS (ESI-QTOF): m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}$ 205.1335; found: 205.1349. $\delta = 6.82$ ppm.

3-[[*tert*-Butyldimethylsilyl]oxy]methyl]-1,2,3,4-tetrahydroisoquinolin-1-one (5a). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–50% EtOAc in petrol. The desired compound was obtained as a 1 : 1 mixture of regioisomers (**5a** and **5b**) that were inseparable by column chromatography. The mixture was a white solid, 93% combined yield (123 mg) from phenylformamido 2,2-dimethylpropanoate (**4**) (0.45 mmol, 100 mg, 1 equiv.). Partial separation of the regioisomers was possible by reverse phase chromatography, eluting 45–65% MeCN in water to give isomer **5a** (18 mg) plus **5b** (16 mg) in pure form with a mixed fraction (60 mg). δ_{H} (400 MHz, chloroform- d) 8.08 (1 H, dd, J 7.6, 1.5), 7.44 (1 H, td, J 7.6, 1.5), 7.39–7.30 (1 H, m), 7.22–7.16 (1 H, m), 6.25 (1 H, brs), 3.87–3.78 (1 H, m), 3.74 (1 H, dd, J 10.0, 1.0), 3.60 (1 H, dd, J 10.0, 8.4), 2.93–2.77 (2 H, m), 0.90 (9 H, s), 0.08 (3 H, s), 0.07 (3 H, s). δ_{C} (101 MHz, CDCl_3) 165.74, 137.25, 132.26, 128.69, 128.14, 127.46, 127.08, 65.66, 52.68, 30.27, 25.83, 18.27, –5.45. HRMS (ESI-QTOF): m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{25}\text{NO}_2\text{Si}$ 292.1728; found 292.1736. $\delta = 2.53$ ppm.

4-[[*tert*-Butyldimethylsilyl]oxy]methyl]-1,2,3,4-tetrahydroisoquinolin-1-one (5b). See above. δ_{H} (400 MHz, chloroform- d) 8.08 (1 H, dd, J 7.6, 1.5), 7.47 (1 H, td, J 7.6, 1.5), 7.38 (1 H, td, J 7.6, 1.5), 7.27–7.21 (1 H, m), 5.96 (1 H, brs), 3.75 (1 H, dd, J 13.6, 10.0), 3.70–3.66 (2 H, m), 3.66 (1 H, dd, J 10.0, 5.4), 3.08–2.97 (1 H, m), 0.89 (9 H, s), 0.03 (3 H, s), 0.03 (3 H, s). δ_{C} (101 MHz, CDCl_3) 165.74, 137.25, 132.26, 128.69, 128.14, 127.77, 127.53, 63.58, 40.61, 40.78, 25.83, 18.27, –5.45. HRMS (ESI-QTOF): m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{25}\text{NO}_2\text{Si}$ 292.1728; found 292.1736. $\delta = 2.62$ ppm.

***tert*-Butyl N-[(1-oxo-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl]carbamate (6a).** Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–50% EtOAc in petrol. The desired compound was obtained as a white solid in 42% yield (53 mg) from phenylformamido 2,2-dimethylpropanoate (**4**) (0.45 mmol, 100 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.82 (1 H, dd, J 7.5, 1.5), 7.80–7.75 (1 H, m), 7.47 (1 H, td, J 7.5, 1.5), 7.33 (1 H, td, J 7.5, 1.2), 7.28 (1 H, d, J 7.5), 6.96 (1 H, t, J 5.9), 3.66–3.47 (1 H, m), 3.12–2.98 (2 H, m), 2.97 (1 H, dd, J 16.0, 5.2), 2.76 (1 H, dd, J 16.0, 8.2), 1.38 (9 H, s). δ_{C} (101 MHz, DMSO- d_6) 164.02, 155.62, 137.52, 131.65, 128.53, 127.79,

126.60, 126.44, 77.86, 50.16, 43.34, 30.34, 27.94. HRMS (ESI-QTOF): m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_3$ 277.1547; found: 277.1558. $\delta = 3.97$ ppm.

***tert*-Butyl N-[(1-oxo-1,2,3,4-tetrahydroisoquinolin-4-yl)methyl]carbamate (6b).** Synthesis and purification described for **6a**. Compound **6b** was obtained as a white solid in 42% yield (54 mg) from phenylformamido 2,2-dimethylpropanoate (**4**) (0.45 mmol, 100 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.85 (1 H, dd, J 7.6, 1.5), 7.74 (1 H, d, J 4.4), 7.49 (1 H, td, J 7.6, 1.5), 7.37 (1 H, td, J 7.6, 1.3), 7.27 (1 H, d, J 7.6), 7.03 (1 H, t, J 5.4), 3.48 (1 H, dd, J 12.7, 4.4), 3.31–3.23 (1 H, m), 3.15–3.05 (2 H, m), 3.03–2.94 (1 H, m), 1.37 (9 H, s). δ_{C} (101 MHz, DMSO- d_6) 163.80, 155.46, 140.29, 131.48, 128.61, 126.91, 126.81, 127.36, 77.61, 40.67, 42.22, 36.89, 28.00. HRMS (ESI-QTOF): m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_3$ 277.1547; found: 277.155. $\delta = 1.08$ ppm.

N-Benzyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (7a). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–50% EtOAc in petrol. The desired compound was obtained as a white solid in 63% yield (40 mg) from phenylformamido 2,2-dimethylpropanoate (**4**) (0.225 mmol, 50 mg, 1 equiv.). δ_{H} (500 MHz, DMSO- d_6) 8.50 (1 H, t, J 6.0), 7.98 (1 H, d, J 4.1), 7.83 (1 H, dd, J 7.6, 1.5), 7.47 (1 H, td, J 7.6, 1.5), 7.35 (1 H, t, J 7.6), 7.27 (1 H, d, J 7.6), 7.25–7.15 (3 H, m), 7.09–6.98 (2 H, m), 4.32–4.12 (3 H, m), 3.29 (1 H, dd, J 16.0, 6.3), 3.16 (1 H, dd, J 16.0, 4.4). δ_{C} (126 MHz, DMSO- d_6) 170.70, 164.21, 139.12, 136.63, 131.57, 129.01, 127.92, 127.42, 126.67, 126.63, 126.59, 126.46, 52.69, 41.89, 30.98. HRMS (ESI-QTOF): m/z $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_2$ 281.1285; found: 281.1298. $\delta = 4.62$ ppm.

3-(Diethoxymethyl)-1,2,3,4-tetrahydroisoquinolin-1-one (8a). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–50% EtOAc in petrol. The desired compound was obtained as a yellow solid in 71% yield (40 mg) from phenylformamido 2,2-dimethylpropanoate (**4**) (0.225 mmol, 50 mg, 1 equiv.). δ_{H} (500 MHz, DMSO- d_6) 7.83 (1 H, dd, J 7.6, 1.4), 7.65–7.603 (1 H, m), 7.46 (1 H, td, J 7.6, 1.5), 7.32 (1 H, td, J 7.6, 1.3), 7.31 (1 H, d, J 7.6), 4.32 (1 H, d, J 6.3), 3.69–3.53 (3 H, m), 3.46 (2 H, dq, J 9.6, 6.9), 3.04 (1 H, dd, J 16.2, 5.7), 2.93 (1 H, dd, J 16.2, 6.9), 1.15–1.03 (6 H, m). δ_{C} (126 MHz, DMSO- d_6) 164.02, 137.58, 132.06, 131.71, 127.13, 126.58, 102.44, 62.53, 51.89, 27.93, 14.98. HRMS (ESI-QTOF): m/z $[\text{M} + \text{H}]^+$ Calcd for 250.1438; found: 250.1454. $\delta = 6.40$ ppm.

6-Bromo-3-[(dimethylamino)methyl]-1,2,3,4-tetrahydroisoquinolin-1-one (13). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–10% MeOH in EtOAc. The desired compound was obtained as a brown solid in 54% yield (70 mg) from (4-bromophenyl)formamido 2,2-dimethylpropanoate (**9**) (0.45 mmol, 135 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.75 (1 H, d, J 8.2), 7.58 (1 H, d, J 2.0), 7.55 (1 H, br s), 7.53 (1 H, dd,



J 8.2, 2.0), 3.71 (1 H, dtdd, J 8.7, 7.1, 4.9, 2.2), 3.02 (1 H, dd, J 16.0, 4.9), 2.79 (1 H, dd, J 16.0, 8.7), 2.33 (1 H, dd, J 12.1, 7.1), 2.25 (1 H, dd, J 12.1, 7.1), 2.16 (6 H, s). δ_{C} (101 MHz, DMSO- d_6) 163.22, 140.42, 130.29, 129.50, 128.88, 128.33, 125.44, 62.44, 47.51, 45.25, 30.78. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{12}H_{15}BrN_2O$ 283.0441; found: 283.0448. δ = 2.47 ppm.

Methyl 3-[(dimethylamino)methyl]-1-oxo-1,2,3,4-tetrahydroisoquinoline-6-carboxylate (14). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–10% MeOH in EtOAc. The desired compound was obtained as a brown solid in 84% yield (100 mg) from methyl 4-[(2,2-dimethylpropanoyl)oxy]carbamoylbenzoate (**11**) (0.45 mmol, 125 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.96 (1 H, dd, J 7.9, 0.7), 7.93–7.86 (2 H, m), 7.72–7.61 (1 H, m), 3.87 (3 H, s), 3.74 (1 H, dtdd, J 8.5, 7.2, 4.9, 2.3), 3.10 (1 H, dd, J 16.0, 4.9), 2.86 (1 H, dd, J 16.0, 8.5), 2.34 (1 H, dd, J 12.1, 7.2), 2.26 (1 H, dd, J 12.1, 7.2), 2.16 (6 H, s). δ_{C} (101 MHz, DMSO- d_6) 165.63, 163.06, 138.37, 132.89, 132.22, 128.44, 127.12, 127.10, 62.49, 52.08, 47.45, 45.25, 30.86. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{14}H_{18}N_2O_3$ 263.1390; found: 263.1412. δ = 8.36 ppm.

7-Bromo-3-[(dimethylamino)methyl]-1,2,3,4-tetrahydroisoquinolin-1-one (15). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–10% MeOH in EtOAc. The desired compound was obtained as a brown solid in 53% yield (68 mg) from (3-bromophenyl)formamido 2,2-dimethylpropanoate (**10**) (0.45 mmol, 135 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.91 (1 H, d, J 2.2), 7.66 (1 H, dd, J 8.0, 2.2), 7.64 (1 H, br s), 7.30 (1 H, d, J 8.0), 3.78–3.63 (1 H, m), 2.99 (1 H, dd, J 16.0, 4.9), 2.76 (1 H, dd, J 16.0, 8.5), 2.32 (1 H, dd, J 12.1, 7.1), 2.25 (1 H, dd, J 12.1, 7.2), 2.16 (6 H, s). δ_{C} (101 MHz, DMSO- d_6) 162.63, 137.28, 134.23, 131.05, 130.13, 129.06, 119.46, 62.43, 47.41, 45.26, 30.42. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{12}H_{15}BrN_2O$ 283.0441; found: 283.0444. δ = 1.06 ppm.

Methyl 3-[(dimethylamino)methyl]-1-oxo-1,2,3,4-tetrahydroisoquinoline-7-carboxylate (16). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–10% MeOH in EtOAc. The desired compound was obtained as a brown solid in 56% yield (67 mg) from methyl 3-[(2,2-dimethylpropanoyl)oxy]carbamoylbenzoate (**12**) (0.45 mmol, 125 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 8.41 (1 H, d, J 1.9), 8.03 (1 H, dd, J 7.9, 1.9), 7.65 (1 H, br s), 7.53–7.43 (1 H, m), 3.87 (3 H, s), 3.75 (1 H, dtdd, J 8.5, 7.1, 4.9, 2.3), 3.10 (1 H, dd, J 16.3, 4.9), 2.88 (1 H, dd, J 16.3, 8.5), 2.34 (1 H, dd, J 12.1, 7.1), 2.26 (1 H, dd, J 12.1, 7.1), 2.16 (6 H, s). δ_{C} (101 MHz, DMSO- d_6) 165.58, 163.31, 143.34, 131.90, 129.31, 128.43, 128.22, 127.46, 62.49, 51.94, 47.33, 45.27, 31.11. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{14}H_{18}N_2O_3$ 263.139; found: 263.1409. δ = 7.22 ppm.

5-[(Dimethylamino)methyl]-4H,5H,6H,7H-thieno[2,3-c]pyridin-7-one (19a). Synthesised following general procedure B. The reaction was carried out at room temperature overnight

then additional catalyst was added and the reaction heated to 50 °C for 3 hours. The crude material was purified by flash column chromatography using a gradient of 0–10% MeOH in EtOAc. The desired compound was obtained as a brown oil in 31% yield (30 mg) from (thiophen-2-yl)formamido 2,2-dimethylpropanoate (**17**) (0.45 mmol, 102 mg, 1 equiv.). Note: minor isomer not isolated. Ratio estimated by LC-MS. δ_{H} (400 MHz, DMSO- d_6) 7.76 (1 H, d, J 4.9), 7.16 (1 H, br s), 7.06 (1 H, d, J 4.9), 3.80 (1 H, dtdd, J 9.2, 7.2, 5.5, 1.8), 2.95 (1 H, dd, J 16.3, 5.5), 2.69 (1 H, dd, J 16.3, 9.2), 2.37 (1 H, dd, J 12.0, 7.2), 2.30 (1 H, dd, J 12.0, 7.2), 2.17 (6 H, s). δ_{C} (101 MHz, DMSO- d_6) 161.38, 143.99, 130.97, 130.55, 127.43, 62.32, 49.35, 45.22, 27.55. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{10}H_{14}N_2OS$ 211.0900; found: 211.0913. δ = 6.16 ppm.

5-[(*tert*-Butyldimethylsilyl)oxy]methyl]-4H,5H,6H,7H-thieno[2,3-c]pyridin-7-one (20a). Synthesised following general procedure B. The reaction was carried out at room temperature overnight then additional catalyst was added and the reaction heated to 50 °C for 3 hours. The crude material was purified by flash column chromatography using a gradient of 0–30% EtOAc in petrol. The desired compound was obtained as a colourless oil in 24% yield (65 mg) from (thiophen-2-yl)formamido 2,2-dimethylpropanoate (**17**) (0.9 mmol, 204 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.75 (1 H, d, J 4.9), 7.50 (1 H, d, J 2.3), 7.06 (1 H, d, J 4.9), 3.72–3.64 (1 H, m), 3.62 (1 H, dd, J 10.0, 4.8), 3.53 (1 H, dd, J 10.0, 7.2), 2.98 (1 H, dd, J 16.6, 6.1), 2.84 (1 H, dd, J 16.6, 6.6), 0.84 (9 H, s), 0.02 (3 H, s), 0.01 (3 H, s). δ_{C} (101 MHz, DMSO- d_6) 161.39, 143.19, 130.26, 130.89, 127.48, 64.05, 52.71, 25.41, 25.49, 17.83, –5.75. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{14}H_{23}NO_2SSi$ 298.1292; found: 298.1299. δ = 2.35 ppm.

4-[(*tert*-Butyldimethylsilyl)oxy]methyl]-4H,5H,6H,7H-thieno[2,3-c]pyridin-7-one (20b). Synthesis and purification described for **20a**. compound **20b** was obtained as a white solid in 55% yield (148 mg) from (thiophen-2-yl)formamido 2,2-dimethylpropanoate (**17**) (0.9 mmol, 204 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.76 (1 H, d, J 5.0), 7.62 (1 H, br s), 7.14 (1 H, dd, J 5.0, 0.4), 3.73 (1 H, dd, J 10.0, 5.4), 3.63 (1 H, dd, J 10.0, 8.5), 3.52 (1 H, ddd, J 12.6, 5.4, 1.9), 3.39 (1 H, ddd, J 12.7, 5.4, 3.4), 3.07 (1 H, dq, J 8.5, 5.4), 0.86 (9 H, s), 0.03 (6 H, s). δ_{C} (101 MHz, DMSO- d_6) 161.35, 145.25, 131.57, 130.59, 126.99, 62.56, 41.76, 37.05, 25.52, 17.83, –5.78. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $C_{14}H_{23}NO_2SSi$ 298.1292; found: 298.1296. δ = 1.34 ppm.

***tert*-Butyl N-({7-oxo-4H,5H,6H,7H-thieno[2,3-c]pyridin-5-yl)methyl}carbamate (21a).** Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–30% EtOAc in petrol. The desired compound was obtained as an off-white solid in 27% yield (35 mg) from (thiophen-2-yl)formamido 2,2-dimethylpropanoate (**17**) (0.45 mmol, 102 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.76 (1 H, d, J 4.9), 7.56 (1 H, br s), 7.04 (1 H, d, J 4.9), 6.97 (1 H, t, J 5.7), 3.75–3.55 (1 H, m), 3.15–3.15 (2 H, m), 2.91 (1 H, dd, J 16.4, 5.6), 2.68 (1 H, dd, J 16.4, 8.8), 1.38



(9 H, s). δ_{C} (101 MHz, DMSO- d_6) 161.38, 155.52, 143.39, 130.94, 130.08, 127.51, 77.84, 51.78, 43.13, 27.92, 26.76. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_{13}\text{H}_{18}\text{N}_2\text{O}_3\text{S}$ 283.1111; found: 283.1114. $\delta = 1.06$ ppm.

tert-Butyl N-((3-bromo-7-oxo-4H,5H,6H,7H-thieno[2,3-c]pyridin-4-yl)methyl)carbamate (21b). Synthesised and purification described for **21a**. Compound **21b** was obtained as a glassy yellow solid in 52% yield (66 mg) from (thiophen-2-yl)formamido 2,2-dimethylpropanoate (**17**) (0.45 mmol, 102 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.77 (1 H, d, J 5.0), 7.61 (1 H, d, J 3.0), 7.09 (1 H, d, J 5.0), 7.04 (1 H, t, J 6.8), 3.47 (1 H, dd, J 12.5, 3.6), 3.31–3.16 (2 H, m), 3.15–2.98 (2 H, m), 1.38 (9 H, s). δ_{C} (101 MHz, DMSO- d_6) 161.50, 155.71, 146.37, 131.35, 130.77, 126.54, 77.76, 42.91, 41.26, 34.83, 27.96. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_{13}\text{H}_{18}\text{N}_2\text{O}_3\text{S}$ 283.1111; found: 283.1112. $\delta = 0.35$ ppm.

3-Bromo-5-[(dimethylamino)methyl]-4H,5H,6H,7H-thieno[2,3-c]pyridin-7-one (22a). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–10% MeOH in EtOAc. The desired compound was obtained as a brown solid in 30% yield (40 mg) from (4-bromothiophen-2-yl)formamido 2,2-dimethylpropanoate (**18**) (0.45 mmol, 137 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.98 (1 H, s), 7.45 (1 H, br s), 3.86 (1 H, dtdd, J 8.8, 7.1, 5.7, 1.9), 2.85 (1 H, dd, J 16.5, 5.7), 2.63 (1 H, dd, J 16.5, 8.8), 2.41–2.28 (2 H, m), 2.17 (6 H, s). δ_{C} (101 MHz, DMSO- d_6) 160.15, 142.42, 131.07, 128.42, 109.82, 62.15, 49.16, 45.25, 26.97. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_{10}\text{H}_{13}\text{BrN}_2\text{OS}$ 289.0005; found: 289.0009. $\delta = 1.38$ ppm.

3-Bromo-5-[(tert-Butyldimethylsilyl)oxy]methyl-4H,5H,6H,7H-thieno[2,3-c]pyridin-7-one (23a). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–30% EtOAc in petrol. The regioisomers were inseparable by column chromatography and were obtained as an approximately 1:2 mixture of a:b as judged by ^1H NMR. The mixture was a white solid in 52% combined yield (88 mg) from (4-bromothiophen-2-yl)formamido 2,2-dimethylpropanoate (**18**) (0.45 mmol, 137 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.96 (1 H, s), 7.77 (1 H, d, J 2.9), 3.82–3.68 (1 H, m), 3.65–3.48 (2 H, m), 2.89 (1 H, dd, J 16.8, 6.6), 2.79 (1 H, dd, J 16.8, 5.5), 0.82 (9 H, s), 0.00 (6 H, s). δ_{C} (101 MHz, DMSO) –5.10, 17.78, 25.52, 26.15, 52.92, 64.84, 109.76, 128.97, 131.00, 141.64, 160.04. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_{14}\text{H}_{22}\text{BrNO}_2\text{SSi}$ 376.0397; found: 376.0391. $\delta = 1.60$ ppm.

3-Bromo-4-[(tert-Butyldimethylsilyl)oxy]methyl-4H,5H,6H,7H-thieno[2,3-c]pyridin-7-one (23b). See the experimental information for **23a**. δ_{H} (400 MHz, DMSO- d_6) 7.99 (1 H, s), 7.80 (1 H, d, J 3.8), 3.60–3.48 (4 H, m), 2.95 (1 H, dtd, J 9.7, 5.3, 2.7), 0.87 (9 H, s), 0.05 (3 H, s), 0.03 (3 H, s). δ_{C} (101 MHz, DMSO) 159.87, 142.60, 132.68, 129.19, 61.34, 41.32, 37.17, 26.26, 17.78, –4.97, –5.06. C–Br not determined. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_{14}\text{H}_{22}\text{BrNO}_2\text{SSi}$ 376.0397; found: 376.0391. $\delta = 1.60$ ppm.

tert-Butyl N-((3-bromo-7-oxo-4H,5H,6H,7H-thieno[2,3-c]pyridin-5-yl)methyl)carbamate (24a). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–30% EtOAc in petrol. The desired compound was obtained as a glassy off white solid in 25% yield (42 mg) from (4-bromothiophen-2-yl)formamido 2,2-dimethylpropanoate (0.45 mmol, 137 mg, 1 equiv.). δ_{H} (400 MHz, chloroform- d) 7.48 (1 H, s), 6.22 (1 H, br s), 4.91 (1 H, br s), 3.99 (1 H, br s), 3.47–3.34 (1 H, m), 3.28 (1 H, dt, J 14.2, 7.0), 2.90 (1 H, dd, J 16.5, 5.6), 2.67 (1 H, dd, J 16.5, 10.0), 1.46 (9 H, s). δ_{C} (101 MHz, CDCl_3) 128.50, 52.92, 44.45, 27.48, 28.31, 162.13, 142.78, 131.18, 110.72. Sidechain NCO not determined. $\text{OC}(\text{Me})_3$ under chloroform resonances. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_{13}\text{H}_{17}\text{BrN}_2\text{O}_3\text{S}$ 361.0216; found: 361.0214. $\delta = 0.55$ ppm.

tert-Butyl N-((3-bromo-7-oxo-4H,5H,6H,7H-thieno[2,3-c]pyridin-4-yl)methyl)carbamate (24b). Synthesis and purification described for **24a**. Compound **24b** was obtained as a glassy off white solid in 29% yield (48 mg) from (4-bromothiophen-2-yl)formamido 2,2-dimethylpropanoate (**18**) (0.45 mmol, 137 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.96 (1 H, s), 7.75 (1 H, d, J 4.5), 7.08 (1 H, br s), 3.55 (1 H, dd, J 13.0, 3.4), 3.41 (1 H, dd, J 13.0, 4.7), 3.08–2.92 (3 H, m), 1.38 (9 H, s). δ_{C} (101 MHz, DMSO) 160.14, 155.56, 144.37, 132.28, 128.60, 109.72, 77.71, 41.82, 34.06, 30.63, 28.21. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_{13}\text{H}_{17}\text{BrN}_2\text{O}_3\text{S}$ 361.0216; found: 361.0211. $\delta = 1.38$ ppm.

6-[(tert-Butyldimethylsilyl)oxy]methyl-2-chloro-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-4-one (26a). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–30% EtOAc in petrol. The regioisomers were inseparable by column chromatography and were obtained as an approximately 1:4 mixture of a:b as judged by ^1H NMR. The mixture was a white solid 36% yield (54 mg) from (2-chloro-1,3-thiazol-5-yl)formamido 2,2-dimethylpropanoate (**25**) (0.45 mmol, 118 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 7.92 (1 H, d, J 2.8), 3.81–3.71 (1 H, m), 3.67–3.58 (2 H, m), 3.13 (1 H, dd, J 17.1, 7.1), 2.95 (1 H, dd, J 17.1, 5.4), 0.81 (9 H, s), 0.00 (6 H, s).

7-[(tert-Butyldimethylsilyl)oxy]methyl-2-chloro-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-4-one (26b). Major regioisomer. δ_{H} (400 MHz, DMSO- d_6) 7.97 (1 H, br s), 3.85 (1 H, dd, J 10.2, 4.4), 3.81–3.74 (1 H, m), 3.66–3.55 (1 H, m), 3.47 (1 H, ddd, J 12.9, 5.9, 3.2), 3.21 (1 H, dtd, J 7.9, 5.9, 4.4), 0.84 (9 H, s), 0.03 (3 H, s), 0.01 (3 H, s).

2-Chloro-6-(hydroxymethyl)-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-4-one (27a). TBAF (0.243 ml, 0.243 mmol, 1.5 eq.) was added to the regioisomeric mixture of silyl ethers **26a** and **b** in THF. The reaction was stirred at room temperature for 1 h then concentrated and purified by preparative HPLC to give the separated regioisomers. Regioisomer **27a** was obtained as a white solid 1.5 mg, 4% yield. δ_{H} (400 MHz, DMSO- d_6) 7.89



(1 H, br s), 4.98 (1 H, m), 3.72 (1 H, dtdd, J 7.5, 6.5, 5.2, 2.4), 3.52–3.37 (2 H, m), 3.06 (1 H, dd, J 17.1, 6.5), 2.94 (1 H, dd, J 17.1, 7.5). δ_{C} (101 MHz, DMSO- d_6) 159.83, 157.00, 154.06, 127.25, 62.66, 52.56, 26.68. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_7\text{H}_7\text{ClN}_2\text{O}_2\text{S}$ 218.9990; found: 218.999. δ = 0.00 ppm.

2-Chloro-7-(hydroxymethyl)-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-4-one (27b). This regioisomer was obtained as a white solid 15 mg, 42% yield. δ_{H} (400 MHz, DMSO- d_6) 7.95 (1 H, br s), 4.97 (1 H, t, J 4.6), 3.69 (1 H, dd, J 9.4, 5.2), 3.64–3.45 (3 H, m), 3.21–3.07 (1 H, m). δ_{C} (101 MHz, DMSO- d_6) 159.82, 158.72, 154.03, 128.63, 60.01, 41.47, 38.34. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_7\text{H}_7\text{ClN}_2\text{O}_2\text{S}$ 218.9990; found 218.9992. δ = 0.91 ppm.

6-(((tert-Butyldimethylsilyl)oxy)methyl)-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-4-one (29a). Synthesised following general procedure B. The reaction was carried out at room temperature and the crude material was purified by flash column chromatography using a gradient of 0–30% EtOAc in petrol. The regioisomers were not separable by column chromatography and were obtained as an approximately 1 : 2 mixture of a : b as judged by ^1H NMR. The mixture was a white solid in 16% yield (22 mg) from (1,3-thiazol-5-yl)formamido 2,2-dimethylpropanoate (0.45 mmol, 102 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 9.22 (1 H, s), 7.77 (1 H, d, J 2.7), 3.81–3.72 (1 H, m), 3.67–3.53 (2 H, m), 3.17 (1 H, dd, J 16.9, 6.8), 3.03 (1 H, dd, J 16.9, 5.8), 0.81 (9 H, s), –0.00 (6 H, s). δ_{C} (101 MHz, DMSO) 158.19, 157.76, 124.64, 51.95, 64.49, 26.57, 25.47, 17.78, –5.76. C=O not determined. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_{13}\text{H}_{22}\text{N}_2\text{O}_2\text{SSi}$ 299.1244; found 299.1247. δ = 1.02 ppm.

7-(((tert-Butyldimethylsilyl)oxy)methyl)-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-4-one (29b). Procedure described for 29a. δ_{H} (400 MHz, DMSO- d_6) 9.25 (1 H, s), 7.85 (1 H, br s), 3.90 (1 H, dd, J 10.1, 4.3), 3.73 (1 H, dd, J 10.1, 8.7), 3.64–3.57 (1 H, m), 3.49 (1 H, ddd, J 12.8, 5.6, 3.2), 3.28–3.22 (1 H, m), 0.85 (9 H, s), 0.04 (3 H, s), 0.02 (3 H, s). δ_{C} (101 MHz, DMSO- d_6) 160.94, 159.47, 157.80, 126.41, 61.84, 41.57, 38.02, 25.47, 17.81, –5.76.

7-Bromo-3-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-2,6-naphthyridin-1-one (31). Synthesised following general procedure B. The reaction mixture was heated to 65 °C for 4 hours then worked up and the crude material was purified by flash column chromatography using a gradient of 0–30% EtOAc in petrol to give a mixture of regioisomers. The major component was isolated by preparative HPLC to give the structure indicated as a white solid in 8% yield (10 mg) from (2-bromopyridin-4-yl)formamido 2,2-dimethylpropanoate (27) (0.45 mmol, 135 mg, 1 equiv.). δ_{H} (400 MHz, DMSO- d_6) 8.46 (1 H, d, J 0.7), 8.12–7.99 (1 H, m), 7.81 (1 H, d, J 0.7), 3.83–3.70 (1 H, m), 3.04 (1 H, dd, J 16.1, 5.0), 2.79 (1 H, dd, J 16.1, 8.1), 2.32 (1 H, dd, J 12.2, 6.8), 2.26 (1 H, dd, J 12.2, 7.5), 2.16 (6 H, s). δ_{C} (101 MHz, DMSO) 161.16, 150.36, 139.56, 138.67, 132.11, 124.10, 62.26, 47.56, 45.32, 27.32. HRMS (ESI-QTOF): m/z $[M + H]^+$ Calcd for $\text{C}_{11}\text{H}_{14}\text{BrN}_3\text{O}$ 284.0393; found 284.0394. δ = 0.23 ppm.

Acknowledgements

The authors warmly thank our Astex colleagues, Stuart Whibley and Nicola Wilsher for providing the HRMS data.

Notes and references

- (a) D. Erlanson, *Introduction to Fragment-Based Drug Discovery*, in *Fragment-Based Drug Discovery and X-Ray Crystallography*, ed. T. G. Davies and M. Hyvönen, Springer, Berlin Heidelberg, 2012, vol. 317, pp. 1–32; (b) R. E. Hubbard and J. B. Murray, Chapter twenty - Experiences in Fragment-Based Lead Discovery, in *Methods in Enzymology*, ed. C. K. Lawrence, Academic Press, 2011, vol. 493, pp. 509–531; (c) T. V. Magee, Progress in discovery of small-molecule modulators of protein–protein interactions via fragment screening, *Bioorg. Med. Chem. Lett.*, 2015, 25(12), 2461–2468; (d) C. W. Murray and D. C. Rees, The rise of fragment-based drug discovery, *Nat. Chem.*, 2009, 1(3), 187–192; (e) E. R. Zartler, Fragonomics: The -Omics with Real Impact, *ACS Med. Chem. Lett.*, 2014, 5(9), 952–953; (f) J. P. Burke, Z. Bian, S. Shaw, B. Zhao, C. M. Goodwin, J. Belmar, C. F. Browning, D. Vigil, A. Friberg, D. V. Camper, O. W. Rossanese, T. Lee, E. T. Olejniczak and S. W. Fesik, Discovery of Tricyclic Indoles That Potently Inhibit Mcl-1 Using Fragment-Based Methods and Structure-Based Design, *J. Med. Chem.*, 2015, 58(9), 3794–3805.
- M. Baker, Fragment-based lead discovery grows up, *Nat. Rev. Drug Discovery*, 2013, 12(1), 5–7.
- G. Bollag, J. Tsai, J. Zhang, C. Zhang, P. Ibrahim, K. Nolop and P. Hirth, Vemurafenib: the first drug approved for BRAF-mutant cancer, *Nat. Rev. Drug Discovery*, 2012, 11(11), 873–886.
- C. W. Murray and D. C. Rees, Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD), *Angew. Chem., Int. Ed.*, 2015, DOI: 10.1002/anie.201506783, published on line Nov 3, 2015.
- (a) M. Congreve, R. Carr, C. Murray and H. Jhoti, A ‘Rule of Three’ for fragment-based lead discovery?, *Drug Discovery Today*, 2003, 8(19), 876–877; (b) H. Jhoti, G. Williams, D. C. Rees and C. W. Murray, The ‘rule of three’ for fragment-based drug discovery: where are we now?, *Nat. Rev. Drug Discovery*, 2013, 12(8), 644–644.
- (a) N. Baurin, F. Aboul-Ela, X. Barril, B. Davis, M. Drysdale, B. Dymock, H. Finch, C. Fromont, C. Richardson, H. Simmonite and R. E. Hubbard, Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets, *J. Chem. Inf. Comput. Sci.*, 2004, 44(6), 2157–2166; (b) N. Blomberg, D. Cosgrove, P. Kenny and K. Kolmodin, Design of compound libraries for fragment screening, *J. Comput. Aided Mol. Des.*, 2009, 23(8), 513–525; (c) J. Fejzo, C. A. Lepre, J. W. Peng, G. W. Bemis, Ajay, M. A. Murcko and J. M. Moore, The SHAPES strategy: an NMR-based approach for lead generation in drug discovery, *Chem. Biol.*, 1999, 6(10), 755–769;



- (d) W. Lau, J. Withka, D. Hepworth, T. Magee, Y. Du, G. Bakken, M. Miller, Z. Hendsch, V. Thanabal, S. Kolodziej, L. Xing, Q. Hu, L. Narasimhan, R. Love, M. Charlton, S. Hughes, W. van Hoorn and J. Mills, Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics, *J. Comput. Aided Mol. Des.*, 2011, **25**(7), 621–636; (e) A. Schuffenhauer, S. Ruedisser, A. Marzinzik, W. Jahnke, P. Selzer and E. Jacoby, Library Design for Fragment Based Screening, *Curr. Top. Med. Chem.*, 2005, **5**(8), 751–762; (f) A. D. Morley, A. Pugliese, K. Birchall, J. Bower, P. Brennan, N. Brown, T. Chapman, M. Drysdale, I. H. Gilbert, S. Hoelder, A. Jordan, S. V. Ley, A. Merritt, D. Miller, M. E. Swarbrick and P. G. Wyatt, Fragment-based hit identification: thinking in 3D, *Drug Discovery Today*, 2013, **18**(23–24), 1221–1227; (g) <http://www.maggichurchousevents.co.uk/bmcs/Downloads/Fragments%20-%20Mon%201115%20Brennan%20Paul.pdf>.
- 7 B. J. Davis and D. A. Erlanson, Learning from our mistakes: the ‘unknown knowns’ in fragment screening, *Bioorg. Med. Chem. Lett.*, 2013, **23**(10), 2844–2852.
- 8 (a) M. M. Hann, A. R. Leach and G. Harper, Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery, *J. Chem. Inf. Comput. Sci.*, 2001, **41**(3), 856–864; (b) A. R. Leach and M. M. Hann, Molecular complexity and fragment-based drug discovery: ten years on, *Curr. Opin. Chem. Biol.*, 2011, **15**(4), 489–496.
- 9 N. Guimond, S. I. Gorelsky and K. Fagnou, Rhodium(III)-Catalyzed Heterocycle Synthesis Using an Internal Oxidant: Improved Reactivity and Mechanistic Studies, *J. Am. Chem. Soc.*, 2011, **133**(16), 6449–6457.
- 10 (a) J. R. Huckins, E. A. Bercot, O. R. Thiel, T.-L. Hwang and M. M. Bio, Rh(III)-Catalyzed C–H Activation and Double Directing Group Strategy for the Regioselective Synthesis of Naphthyridinones, *J. Am. Chem. Soc.*, 2013, **135**(39), 14492–14495; (b) T. K. Hyster, D. M. Dalton and T. Rovis, Ligand design for Rh(III)-catalyzed C–H activation: an unsymmetrical cyclopentadienyl group enables a regioselective synthesis of dihydroisoquinolones, *Chem. Sci.*, 2015, **6**(1), 254–258; (c) S. Rakshit, C. Grohmann, T. Besset and F. Glorius, Rh(III)-Catalyzed Directed C–H Olefination Using an Oxidizing Directing Group: Mild, Efficient, and Versatile, *J. Am. Chem. Soc.*, 2011, **133**(8), 2350–2353; (d) T. K. Hyster, L. Knörr, T. R. Ward and T. Rovis, Biotinylated Rh(III) Complexes in Engineered Streptavidin for Accelerated Asymmetric C–H Activation, *Science*, 2012, **338**(6106), 500–503; (e) B. Ye and N. Cramer, Chiral cyclopentadienyl ligands as stereocontrolling element in asymmetric C–H functionalization, *Science*, 2012, **338**(6106), 504–506.
- 11 N. J. Webb, S. P. Marsden and S. A. Raw, Rhodium(III)-Catalyzed C–H Activation/Annulation with Vinyl Esters as an Acetylene Equivalent, *Org. Lett.*, 2014, **16**(18), 4718–4721.
- 12 B. Ye and N. Cramer, Asymmetric Synthesis of Isoindolones by Chiral Cyclopentadienyl-Rhodium(III)-Catalyzed C–H Functionalizations, *Angew. Chem., Int. Ed.*, 2014, **53**(30), 7896–7899.
- 13 D. Dou, P. Viwanathan, Y. Li, G. He, K. R. Alliston, G. H. Lushington, J. D. Brown-Clay, R. Padmanabhan and W. C. Groutas, Design, Synthesis, and In Vitro Evaluation of Potential West Nile Virus Protease Inhibitors Based on the 1-Oxo-1,2,3,4-tetrahydroisoquinoline and 1-Oxo-1,2-dihydroisoquinoline Scaffolds, *J. Comb. Chem.*, 2010, **12**(6), 836–843.
- 14 S. Wu, R. Zeng, C. Fu, Y. Yu, X. Zhang and S. Ma, Rhodium-catalyzed C–H functionalization-based approach to eight-membered lactams, *Chem. Sci.*, 2015, **6**(4), 2275–2285.
- 15 N. Guimond, C. Gouliaras and K. Fagnou, Rhodium(III)-Catalyzed Isoquinolone Synthesis: The N–O Bond as a Handle for C–N Bond Formation and Catalyst Turnover, *J. Am. Chem. Soc.*, 2010, **132**(20), 6908–6909.
- 16 M. Pesset, D. Oehrich, F. Rombouts and G. A. Molander, Complementary Regioselectivity in Rh(III)-Catalyzed Insertions of Potassium Vinyltrifluoroborate via C–H Activation: Preparation and Use of 4-Trifluoroboratotetrahydroisoquinolones, *Org. Lett.*, 2013, **15**(7), 1528–1531.
- 17 A. Nadin, C. Hattotuagama and I. Churcher, Lead-Oriented Synthesis: A New Opportunity for Synthetic Chemistry, *Angew. Chem., Int. Ed.*, 2012, **51**(5), 1114–1122.
- 18 Z. Zhang, Y. Yu and L. S. Liebeskind, N-Amidation by Copper-Mediated Cross-Coupling of Organostannanes or Boronic Acids with O-Acetyl Hydroxamic Acids, *Org. Lett.*, 2008, **10**(14), 3005–3008.
- 19 R. D. Farrant, J. C. Hollerton, S. M. Lynn, S. Provera, P. J. Sidebottom and R. J. Upton, NMR quantification using an artificial signal, *Magn. Reson. Chem.*, 2010, **48**(10), 753–762.

